샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758897

세계의 죽상동맥경화증 치료제 시장

Atherosclerosis Therapeutics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 181 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

죽상동맥경화증 치료제 세계 시장은 2030년까지 137억 달러에 달할 전망

2024년에 111억 달러로 추정되는 죽상동맥경화증 치료제 세계 시장은 분석 기간인 2024-2030년에 CAGR 3.5%로 성장하여 2030년에는 137억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 죽상동맥경화증 저분자 제제는 CAGR 4.3%를 기록하며 분석 기간 종료까지 92억 달러에 달할 것으로 예측됩니다. 죽상동맥경화증 생물학적 제제 부문의 성장률은 분석 기간 동안 CAGR 2.0%로 추정됩니다.

미국 시장은 30억 달러로 추정, 중국은 CAGR 6.7%로 성장 예측

미국의 죽상동맥경화증 치료제 시장은 2024년에 30억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 28억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.7%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.4%와 2.8%로 예측됩니다. 유럽에서는 독일이 CAGR 2.0%로 성장할 것으로 예측됩니다.

세계의 죽상동맥경화증 치료제 시장 - 주요 동향과 촉진요인 정리

의학의 발전에도 불구하고 죽상동맥경화증은 왜 여전히 세계 보건의 위기인가?

동맥벽에 플라크가 점진적으로 축적되는 동맥경화증은 여전히 전 세계 심혈관질환의 주요 원인 중 하나입니다. 수십 년에 걸친 연구와 효과적인 치료 개입에도 불구하고, 심장마비, 뇌졸중, 말초동맥질환으로 인해 매년 수백만 명이 목숨을 잃는 일이 계속되고 있습니다. 이러한 지속적인 유병률은 건강에 해로운 식습관, 좌식 생활, 흡연, 스트레스 증가와 같은 생활습관이 플라크 형성의 위험을 증가시키는 데에 기인합니다. 또한, 죽상동맥경화증은 급성 심혈관계 질환으로 나타나기 전에 수십 년 동안 조용히 진행되는 경우가 많아 조기 발견과 개입이 특히 어려운 질환입니다. 세계화로 인해 서유럽식 식습관이 도입되고 도시화로 인해 신체 활동이 감소함에 따라 고소득 국가와 개발도상국의 인구가 점점 더 많은 영향을 받고 있습니다. 이 문제를 더욱 심각하게 만드는 것은 당뇨병, 고혈압, 비만과 같은 합병증의 증가이며, 이는 모두 동맥경화의 진행을 촉진하는 중요한 요인입니다. 또한, 인구통계학적 변화, 특히 고령화 인구의 증가로 인해 동맥경화증과 관련된 합병증의 위험에 노출되어 있거나 이미 동맥경화증을 앓고 있는 환자가 증가하고 있습니다. 스타틴 및 기타 지질 강하제는 콜레스테롤 수치 관리에 효과적임이 입증되었지만, 특정 고위험군에 대해서는 충분히 활용되지 않거나 불충분한 경우가 많습니다. 또한, 환자의 순응도, 의료 서비스 접근성 제한, 무증상 진행도 효과적인 질환 관리를 방해하는 요인으로 작용하고 있습니다. 이러한 다각적인 문제들은 죽상동맥경화증이 여전히 세계 보건의 시급한 과제인 이유를 강조하며, 보다 정교하고 접근성이 높으며 개인화된 치료 접근법의 필요성을 강조하고 있습니다.

혁신은 동맥경화 치료의 상황을 어떻게 변화시키고 있는가?

죽상동맥경화증 치료법은 생명공학, 정밀의료, 분자생물학 연구의 발전에 힘입어 큰 변화를 맞이하고 있습니다. 스타틴, 항혈소판제 등 전통적인 치료법은 여전히 치료의 근간을 이루고 있습니다. PCSK9 억제제와 같은 단클론항체들은 지질 관리에 그치지 않고 플라크 축적을 유발하는 근본적인 염증 및 면역 경로를 다루는 새로운 접근법이 등장하고 있으며, PCSK9 억제제와 같은 단클론항체들은 기존 약물로는 달성할 수 없었던 콜레스테롤 저하를 달성할 수 있는 새로운 지질 강하 치료의 시대를 열었습니다. 콜레스테롤을 낮출 수 있습니다. 이러한 생물학적 제제는 가족성 고콜레스테롤혈증 환자 및 스타틴 불내성 환자에게 특히 유용하며, CRISPR을 포함한 유전자 편집 기술도 지질 대사와 관련된 유전자를 변형시켜 장기적으로 동맥경화를 예방할 수 있는 가능성을 연구하고 있습니다. 또 다른 성장 분야는 지질 합성과 염증에 관여하는 특정 유전자 표적을 침묵시킬 수 있는 RNA 기반 치료제입니다. 혈관내 초음파 및 빛 간섭 단층촬영과 같은 영상 기술은 플라크의 특성을 모니터링하고 치료 반응을 실시간으로 평가하기 위해 현재 치료 전략과 통합되고 있습니다. 약물 용출 스텐트 및 혈관 스커폴드는 안전성과 유효성 측면에서 진화하고 있으며, 전신 약물 요법을 보완하는 국소 요법을 제공하고 있습니다. 또한, 디지털 헬스 툴과 웨어러블 디바이스의 사용으로 지속적인 심혈관 모니터링과 개별화된 치료 조정이 가능해졌습니다. 이러한 혁신은 고위험군 환자의 예후를 개선할 뿐만 아니라 동맥경화증의 진단, 모니터링 및 임상적 지속 기간 동안 동맥경화증을 관리하는 방법을 재정의하고 있습니다.

어떤 외부적 요인이 치료제 개발의 방향을 이끌고 있는가?

과학적 발전뿐만 아니라 의료 정책, 규제 프레임워크, 경제적 격차, 대중의 인식 개선 캠페인 등 외부 요인이 죽상동맥질환 치료제 시장 형성에 매우 중요한 역할을 하고 있습니다. 전 세계 심혈관질환의 부담을 줄이기 위한 정부 주도의 이니셔티브는 특히 급속한 도시화와 생활양식의 변화를 겪고 있는 지역에서 보다 광범위한 검진 프로그램과 예방 요법에 대한 자금 지원을 가져오고 있습니다. 규제 당국은 표준 치료에 반응하지 않는 고위험군 죽상동맥경화증 환자들을 위한 획기적인 치료법을 신속히 승인하기 시작했습니다. 동시에 제약사들은 높은 시장 잠재력과 미충족 수요를 바탕으로 신규 화합물 개발에 적극적으로 투자하고 있습니다. 의료 시스템은 단발성 치료보다는 조기 개입과 장기적인 질병 관리에 인센티브를 부여하는 가치 기반 치료 모델을 점점 더 선호하고 있습니다. 이러한 모델은 콜레스테롤을 낮추는 것뿐만 아니라 심혈관 사건과 사망률을 낮추는 치료제의 채택을 촉진합니다. 또한, 사회경제적 격차는 치료 접근성에 계속 영향을 미치고 있으며, 많은 중산층과 저소득층은 고급 치료를 받거나 일관된 후속 치료를 유지하는 데 어려움을 겪고 있습니다. 이에 따라 매일의 복약 순응도 부담을 줄여주는 비용 효율적인 제네릭 및 장기 지속형 약물의 개발에 대한 관심이 높아지고 있습니다. 동맥경화증에 대한 환자들의 이해를 높이고 조기 진료를 독려하는 공공 교육 및 인식 개선 캠페인도 진단 및 치료 솔루션에 대한 수요를 뒷받침하고 있습니다. 이러한 규제, 경제, 사회적 요인의 상호작용은 죽상동맥경화증 치료제 분야의 기술 혁신의 속도와 집중도를 결정하는 데 중요한 역할을 하고 있습니다.

죽상동맥경화증 치료제 시장의 성장 동력은 무엇인가?

죽상동맥경화증 치료제 시장의 성장은 인구 동향, 과학 발전, 의료 서비스 제공 모델의 진화에 기반한 몇 가지 요인에 의해 주도되고 있습니다. 가장 중요한 요인 중 하나는 세계 인구의 고령화이며, 심혈관 위험인자의 유병률이 높아짐에 따라 장기적인 죽상동맥경화증 관리에 대한 수요가 증가할 것입니다. 동시에 비만, 제2형 당뇨병, 대사증후군과 같은 생활습관병이 증가하면서 동맥경화 및 관련 합병증 치료를 필요로 하는 환자층이 확대되고 있습니다. 약리유전체학 및 정밀의료의 발전은 보다 타겟팅된 치료 개입을 가능하게 하고, 효능을 높이고 부작용을 감소시키고 있습니다. 또한, 의료진은 원격 모니터링 및 치료 순응도를 지원하는 디지털 도구를 도입하고 있으며, PCSK9 억제제, CETP 억제제, 항염증제 등 새로운 약물 계열의 등장으로 기존 약물에 내성이 있는 환자, 특히 1차 선택 약물에 내성이 있는 환자들에게 치료 옵션을 제공하고 있습니다. 1차 치료제에 내성을 보이는 환자들에게 치료 선택의 폭이 넓어지고 있습니다. 지불자와 보험사들은 조기에 적극적으로 치료하는 것이 장기적으로 의료비 절감에 비용 효율적이라는 것을 인식하기 시작했으며, 이는 첨단 치료에 대한 보다 유리한 상환 정책으로 이어지고 있습니다. 또한, 현재 진행 중인 임상시험과 규제 당국의 승인으로 새로운 파이프라인 후보물질이 꾸준히 시장에 출시되고 있으며, 기술 혁신의 모멘텀이 증가하고 있습니다. 생활습관 관리, 진단, 약물 중재를 포함한 전인적 심혈관 치료로의 전환은 복합적 치료 접근법에 대한 수요를 강화하고 있습니다. 그 결과, 죽상동맥경화증 치료제 시장은 임상적 요구, 기술 발전, 전략적 의료 계획의 조합으로 인해 시장 규모가 확대될 뿐만 아니라 그 범위도 다양해지고 있습니다.

부문

제품(죽상동맥경화증 치료용 저분자 제제, 죽상동맥경화증 치료용 생물학적 제제)

조사 대상 기업 사례(총 43개사)

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc(GSK)
  • Ionis Pharmaceuticals, Inc.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Co.
  • Teijin Pharma Limited
  • Zai Lab Limited

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장과 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.07.18

Global Atherosclerosis Therapeutics Market to Reach US$13.7 Billion by 2030

The global market for Atherosclerosis Therapeutics estimated at US$11.1 Billion in the year 2024, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Atherosclerosis Small Molecules, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Atherosclerosis Biologics segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 6.7% CAGR

The Atherosclerosis Therapeutics market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Atherosclerosis Therapeutics Market - Key Trends & Drivers Summarized

Why Is Atherosclerosis Still a Global Health Crisis Despite Medical Advances?

Atherosclerosis, characterized by the progressive buildup of plaque in arterial walls, remains one of the leading contributors to cardiovascular diseases worldwide. Despite decades of research and the availability of effective therapeutic interventions, it continues to claim millions of lives annually due to heart attacks, strokes, and peripheral arterial disease. This persistent prevalence is partly due to lifestyle factors such as unhealthy diets, sedentary behavior, smoking, and increasing stress levels that collectively elevate the risk of plaque formation. Furthermore, atherosclerosis often develops silently over decades before manifesting in acute cardiovascular events, which makes early detection and intervention particularly challenging. Populations in both high-income and developing countries are increasingly affected as globalization introduces western dietary habits and urbanization contributes to reduced physical activity. Compounding this issue is the rise in coexisting conditions such as diabetes, hypertension, and obesity, all of which are significant accelerators of atherosclerotic progression. Moreover, demographic shifts, especially the global increase in aging populations, have resulted in a growing patient base at risk of or already suffering from atherosclerosis-related complications. Although statins and other lipid-lowering agents have proven effective in managing cholesterol levels, they are often underutilized or insufficient for certain high-risk populations. Patient adherence, limited access to healthcare, and asymptomatic progression also hinder effective disease control. These multifaceted challenges emphasize why atherosclerosis remains an urgent global health concern and highlight the need for more sophisticated, accessible, and personalized therapeutic approaches.

How Is Innovation Reshaping the Landscape of Atherosclerosis Treatment?

The therapeutic landscape for atherosclerosis is undergoing significant transformation, fueled by advancements in biotechnology, precision medicine, and molecular research. Traditional therapies, such as statins and antiplatelet drugs, continue to form the cornerstone of treatment; however, new approaches are emerging that go beyond lipid management to address the underlying inflammatory and immune pathways driving plaque buildup. Monoclonal antibodies, such as PCSK9 inhibitors, have introduced a new era of lipid-lowering therapies that can achieve cholesterol reductions previously unattainable through conventional drugs. These biologics are particularly useful for patients with familial hypercholesterolemia or those who are statin-intolerant. Gene-editing technologies, including CRISPR, are also being explored to modify genes associated with lipid metabolism, potentially offering long-term protection against atherosclerosis. Another area of growth is RNA-based therapeutics, which can silence specific genetic targets involved in lipid synthesis or inflammation. Imaging technologies, such as intravascular ultrasound and optical coherence tomography, are now being integrated with treatment strategies to monitor plaque characteristics and assess therapeutic responses in real time. Drug-eluting stents and vascular scaffolds have evolved in both safety and efficacy, providing localized therapy that complements systemic medication. Additionally, the use of digital health tools and wearable devices is allowing for continuous cardiovascular monitoring and personalized treatment adjustments. Collectively, these innovations are not only improving outcomes for high-risk patients but also redefining how atherosclerosis is diagnosed, monitored, and managed across its entire clinical continuum.

What External Forces Are Steering the Direction of Therapeutic Development?

Beyond the scientific advancements, external factors such as healthcare policy, regulatory frameworks, economic disparities, and public awareness campaigns are playing pivotal roles in shaping the atherosclerosis therapeutics market. Government-led initiatives aimed at reducing the global burden of cardiovascular disease are resulting in broader screening programs and funding for preventive therapies, particularly in regions experiencing rapid urbanization and lifestyle shifts. Regulatory bodies are beginning to fast-track approvals for breakthrough therapies addressing high-risk atherosclerosis patients who fail to respond to standard treatments. At the same time, pharmaceutical companies are investing more aggressively in developing novel compounds, driven by the high market potential and unmet clinical needs. Health systems are increasingly favoring value-based care models, which incentivize early intervention and long-term disease management over episodic treatment. These models promote the adoption of therapeutics that not only lower cholesterol but also demonstrate reductions in cardiovascular events and mortality. Furthermore, socioeconomic disparities continue to influence treatment accessibility, with many low- and middle-income populations struggling to afford advanced therapies or maintain consistent follow-up care. This has led to increased interest in developing cost-effective generic formulations and long-acting drugs that reduce the burden of daily medication adherence. Public education and awareness campaigns are also improving patient understanding of atherosclerosis and encouraging earlier consultations, thereby supporting demand for diagnostic and therapeutic solutions. The interplay of these regulatory, economic, and societal factors is instrumental in directing the pace and focus of innovation within the atherosclerosis therapeutics sector.

What Factors Are Driving Growth in the Atherosclerosis Therapeutics Market?

The growth in the atherosclerosis therapeutics market is driven by several factors rooted in demographic trends, scientific advancement, and evolving healthcare delivery models. One of the most significant drivers is the aging global population, which presents a higher prevalence of cardiovascular risk factors, thereby increasing the demand for long-term atherosclerosis management. Simultaneously, the rising incidence of lifestyle-related conditions such as obesity, type 2 diabetes, and metabolic syndrome is expanding the pool of patients requiring treatment for atherosclerosis or its associated complications. Advances in pharmacogenomics and precision medicine are enabling more targeted therapeutic interventions, boosting efficacy and reducing adverse effects. In addition, healthcare providers are increasingly integrating digital tools that support remote monitoring and treatment adherence, thus expanding the market for supportive therapeutics that complement traditional medications. The entry of novel drug classes, including PCSK9 inhibitors, CETP inhibitors, and anti-inflammatory agents, is further enhancing therapeutic options, especially for patients resistant to first-line treatments. Payers and insurers are beginning to recognize the cost-effectiveness of early and aggressive treatment in reducing long-term healthcare expenditures, leading to more favorable reimbursement policies for advanced therapies. Furthermore, ongoing clinical trials and regulatory approvals are introducing new pipeline candidates into the market at a steady pace, keeping innovation momentum high. The shift toward holistic cardiovascular care, encompassing lifestyle management, diagnostics, and pharmaceutical intervention, is reinforcing the demand for multi-modal therapeutic approaches. As a result, the market for atherosclerosis therapeutics is not only expanding in volume but also diversifying in scope, driven by a combination of clinical need, technological evolution, and strategic healthcare planning.

SCOPE OF STUDY:

The report analyzes the Atherosclerosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Atherosclerosis Small Molecules, Atherosclerosis Biologics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Ionis Pharmaceuticals, Inc.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Co.
  • Teijin Pharma Limited
  • Zai Lab Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Atherosclerosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Cardiovascular Diseases Spurs Demand for Atherosclerosis Therapeutics
    • Increased Focus on Preventive Cardiology Drives Development of Early-stage Treatment Options
    • Boom in Aging Populations and Lifestyle-related Risk Factors Expands the Addressable Market
    • Growing Emphasis on Personalized Medicine Throws the Spotlight on Targeted Atherosclerosis Therapies
    • Advances in Lipid-lowering Agents and Anti-inflammatory Drugs Propel Pipeline Innovation
    • Demand for Combination Therapies and Multimodal Treatment Strategies Strengthens Clinical Adoption
    • Here's How Biomarker-driven Approaches Enhance Precision and Treatment Efficacy
    • Wider Integration of AI in Drug Discovery and Trial Design Generates Acceleration in R&D
    • Rising Investment in RNA-based and Gene-editing Platforms Sustains Innovation in Next-gen Therapeutics
    • Expansion of Cardiometabolic Care Models Unlocks New Opportunities for Holistic Treatment Protocols
    • Growing Use of Imaging and Diagnostic Tools Fuels Early Detection and Therapeutic Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Atherosclerosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Atherosclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Atherosclerosis Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Atherosclerosis Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Atherosclerosis Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Atherosclerosis Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Atherosclerosis Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Atherosclerosis Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • JAPAN
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • CHINA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • EUROPE
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Atherosclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • FRANCE
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • GERMANY
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • INDIA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Atherosclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Atherosclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • AFRICA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제